DexCom, Inc. (DXCM) Stock Price: $78.19+1.57 (+2.05%)
The total return cagr for DexCom, Inc. (DXCM) stock is -8.75% over the past 12 months. The 3 year average growth rate is -14.32% and the 5 year cagr is -4.32%. Total return includes dividends reinvested.
The closing share price for DexCom, Inc. (DXCM) stock was $78.19 for Tuesday, June 9, 2026, up +2.05% from the previous day.
DXCM Price Chart
DXCM Key Metrics
See All MetricsDXCM Earnings Preview
Next Earnings Date
Jul 29, 2026
50 days away
EPS Estimate
0.61
Revenue Est.
$1.29B
Last Quarter Results
EPS
$0.56
vs Estimate
$0.47
Revenue
$1.19B
vs Estimate
$1.17B
DXCM Analyst Ratings
Consensus Rating
Based on 24 analysts
Average Price Target
$83.00
+6.2% upside
Low
$65.00
Current
$78.19
High
$112.00
DXCM Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $0.64 | N/A | 5 |
| Q2 2027 | N/A | $0.72 | N/A | 5 |
| Q3 2027 | N/A | $0.79 | N/A | 5 |
| Q4 2027 | N/A | $0.88 | N/A | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $3.08 | N/A | 14 |
| FY 2028 | N/A | $3.68 | N/A | 5 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $1.33B | N/A | 5 |
| Q2 2027 | N/A | $1.44B | N/A | 5 |
| Q3 2027 | N/A | $1.48B | N/A | 5 |
| Q4 2027 | N/A | $1.55B | N/A | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $5.83B | N/A | 14 |
| FY 2028 | N/A | $6.51B | N/A | 5 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
DXCM Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1DXCM | $30.17B | $78.19 | +2.05% | -8.75% | -4.32% | +15.71% |
DXCM Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach